Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lactobacillus reuteri LacA is a specialized beta-galactosidase enzyme belonging to the Glycoside Hydrolase family 42 (GH42), primarily found in the probiotic bacterium Limosilactobacillus reuteri (formerly Lactobacillus reuteri). Unlike the more common GH2 family beta-galactosidases that specialize in lactose hydrolysis, LacA is specifically adapted to degrade complex galactooligosaccharides (GOS) and alpha-galactosides such as raffinose and stachyose [1, 6, 16]. This enzymatic activity is crucial for the ecological fitness and competitive colonization of L. reuteri within the human gastrointestinal tract, as it allows the bacterium to utilize specific dietary fibers as a primary energy source [1, 2, 10]. In clinical and biotechnological contexts, LacA is considered a key component of synbiotic therapies, where prebiotics like GOS are administered to selectively promote the growth and metabolic activity of the probiotic [3, 4, 10]. By facilitating the breakdown of these substrates, LacA supports the probiotic's ability to modulate the host immune system, strengthen the intestinal barrier, and produce beneficial metabolites like short-chain fatty acids [5, 7, 12]. Furthermore, its activity contributes to the alleviation of symptoms associated with lactose intolerance and infant colic by assisting in the digestion of galactose-containing sugars [11, 12].
Hydrolysis of terminal beta-galactosyl residues from galactooligosaccharides and other beta-galactosides to provide a carbon source for the probiotic bacterium, thereby enhancing its survival, colonization, and beneficial metabolic activity in the host gastrointestinal tract.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lactobacillus reuteri beta-galactosidase (LacA) (LacA).